Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Canada Postdoctoral Research Award (CPRA) program

University of Calgary

$140,000.00

Neurochemical and cognitive mechanisms underlying psilocybin-assisted psychotherapy for alcohol use disorder: A randomized, controlled clinical trial

FY 2025-26

Summary
Alcohol use disorder (AUD) is a common mental health burden in Canada. Unfortunately, there are not many effective treatments, and the ones that do exist are demanding, leading to only a small fraction of AUD patients seeking pharmacology-based therapies. There is a clear and urgent need for the development of novel pharmacotherapies in AUD. Recently, there has been growing interest in the use of psychedelic drugs, such as psilocybin (the active component in magic mushrooms), to treat psychiatric conditions. Research has shown an increase in cognitive flexibility in depressive patients following a single psychoactive dose of psilocybin. AUD patients with lower cognitive flexibility are at higher risk of poor treatment response. Therefore, we hypothesize that psilocybin will enhance the response to therapy in individuals with AUD, compared to placebo, by increasing cognitive flexibility. We will also use MRI to explore how psilocybin changes concentrations of neurometabolites in the brain, in order to get a better understanding of its mechanisms of action. This study will address the need for more effective, alternative treatments for AUD, and expand our understanding of the neurobiological mechanisms underlying both the disorder and psychedelic drugs.
Program
Canada Postdoctoral Research Award (CPRA) program
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
536712
Name
Tansey Ryann C
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Neurochemical and cognitive mechanisms underlying psilocybin-assisted psychotherapy for alcohol use disorder: A randomized, controlled clinical trial
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Alcohol Use Disorder; Cognitive Flexibility; Magnetic Resonance Spectroscopy; Neuroimaging; Psilocybin-Assisted Psychotherapy; Psychedelics
Abstract
Alcohol use disorder (AUD) is a common mental health burden in Canada. Unfortunately, there are not many effective treatments, and the ones that do exist are demanding, leading to only a small fraction of AUD patients seeking pharmacology-based therapies. There is a clear and urgent need for the development of novel pharmacotherapies in AUD. Recently, there has been growing interest in the use of psychedelic drugs, such as psilocybin (the active component in magic mushrooms), to treat psychiatric conditions. Research has shown an increase in cognitive flexibility in depressive patients following a single psychoactive dose of psilocybin. AUD patients with lower cognitive flexibility are at higher risk of poor treatment response. Therefore, we hypothesize that psilocybin will enhance the response to therapy in individuals with AUD, compared to placebo, by increasing cognitive flexibility. We will also use MRI to explore how psilocybin changes concentrations of neurometabolites in the brain, in order to get a better understanding of its mechanisms of action. This study will address the need for more effective, alternative treatments for AUD, and expand our understanding of the neurobiological mechanisms underlying both the disorder and psychedelic drugs.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Tansey, Ryann C
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~